Fig. 5: In vivo effects of chronic treatment with harmol.

a Body weight of obese C57BL/6JHsdOla male mice (previously fed with HFD for 4 months since they were 12 weeks old) kept on HFD and treated with vehicle (water, W), 100 mg/kg harmol (H) or 10 mg/kg rosiglitazone in their drinking water for 3 months. b Average food intake in the same mice described in (a) during all the time of treatment with the indicated compounds (n = 3 cages/condition). At the end of the treatment indicated for (a), the same n = 8 mice were measured for their fat mass (c); lean mass (d); glycemia recorded after 16 h of fasting (e); glucose tolerance test (f; area under the curve is shown in (g)); insulinemia (h) and HOMA-IR (i) after 16 hours of fasting; energy expenditure (EE, j) and respiratory quotient (RQ, k) with their corresponding average values during day and night shown to the right; weight of the indicated tissues (l); liver macroscopic appearance (m); lipid and triglyceride content in the liver (n, o); blood adiponectin (AD) and transferrin (TF) measured by Western blot (p), with the band quantification shown in (q); and spermidine levels in the liver (r). Bars and line-connected dots represent the average of the indicated number of individuals. Dots in bar graphs (b–e, g–k, n, o, q, r) represent samples or measures from independent animals. Error bars represent the standard error of the mean. Statistical significance was assessed using the two-way ANOVA test with Tukey correction for multiple comparisons (a, f); and the one-way ANOVA test with Tukey correction for multiple comparisons in panels b–e, g–I, l, and n–r. P values are indicated when P < 0.05. Source data are provided as a Source Data file.